iTeos Therapeutics (ITOS) Competitors $7.47 +0.12 (+1.63%) (As of 12/24/2024 04:01 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ITOS vs. RCKT, BCYC, AVDL, COLL, SEPN, ZYME, BCAX, GYRE, PSTX, and PAHCShould you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Rocket Pharmaceuticals (RCKT), Bicycle Therapeutics (BCYC), Avadel Pharmaceuticals (AVDL), Collegium Pharmaceutical (COLL), Septerna (SEPN), Zymeworks (ZYME), Bicara Therapeutics (BCAX), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. iTeos Therapeutics vs. Rocket Pharmaceuticals Bicycle Therapeutics Avadel Pharmaceuticals Collegium Pharmaceutical Septerna Zymeworks Bicara Therapeutics Gyre Therapeutics Poseida Therapeutics Phibro Animal Health Rocket Pharmaceuticals (NASDAQ:RCKT) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability. Which has better earnings and valuation, RCKT or ITOS? iTeos Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRocket PharmaceuticalsN/AN/A-$245.60M-$2.75-4.25iTeos Therapeutics$35M7.80-$112.64M-$3.15-2.37 Does the media favor RCKT or ITOS? In the previous week, Rocket Pharmaceuticals had 10 more articles in the media than iTeos Therapeutics. MarketBeat recorded 12 mentions for Rocket Pharmaceuticals and 2 mentions for iTeos Therapeutics. Rocket Pharmaceuticals' average media sentiment score of 0.57 beat iTeos Therapeutics' score of -0.46 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive iTeos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in RCKT or ITOS? 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are held by institutional investors. 28.5% of Rocket Pharmaceuticals shares are held by insiders. Comparatively, 12.5% of iTeos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend RCKT or ITOS? Rocket Pharmaceuticals currently has a consensus price target of $48.80, indicating a potential upside of 317.81%. iTeos Therapeutics has a consensus price target of $22.25, indicating a potential upside of 197.86%. Given Rocket Pharmaceuticals' higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than iTeos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92iTeos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer RCKT or ITOS? Rocket Pharmaceuticals received 350 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 78.43% of users gave iTeos Therapeutics an outperform vote while only 73.17% of users gave Rocket Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRocket PharmaceuticalsOutperform Votes39073.17% Underperform Votes14326.83% iTeos TherapeuticsOutperform Votes4078.43% Underperform Votes1121.57% Which has more risk and volatility, RCKT or ITOS? Rocket Pharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Is RCKT or ITOS more profitable? iTeos Therapeutics' return on equity of -20.11% beat Rocket Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rocket PharmaceuticalsN/A -62.62% -54.17% iTeos Therapeutics N/A -20.11%-17.50% SummaryRocket Pharmaceuticals and iTeos Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Ad StocksToTradeAfter New Years, price goes back up 4,800%When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!Click here to review Tim’s special Holiday offer before it’s too late. Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITOS vs. The Competition Export to ExcelMetriciTeos TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$272.91M$2.96B$5.22B$9.27BDividend YieldN/A1.91%5.12%4.30%P/E Ratio-2.3745.6887.3417.27Price / Sales7.80417.611,166.41119.61Price / CashN/A174.7643.2337.83Price / Book0.463.924.834.93Net Income-$112.64M-$42.00M$120.46M$225.34M7 Day Performance2.89%3.88%2.84%4.14%1 Month Performance-9.34%-0.22%19.70%1.16%1 Year Performance-31.47%18.86%30.57%16.98% iTeos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITOSiTeos Therapeutics3.5047 of 5 stars$7.47+1.6%$22.25+197.9%-31.5%$272.91M$35M-2.3790RCKTRocket Pharmaceuticals4.8252 of 5 stars$11.96-0.5%$51.00+326.4%-61.2%$1.09BN/A-4.37240BCYCBicycle Therapeutics3.7974 of 5 stars$15.39+11.4%$36.00+133.9%-21.3%$1.06B$26.98M-4.56240High Trading VolumeAVDLAvadel Pharmaceuticals2.6936 of 5 stars$10.94+5.3%$24.43+123.3%-25.9%$1.05B$138.16M-13.15154Positive NewsCOLLCollegium Pharmaceutical3.7303 of 5 stars$30.68+2.0%$42.60+38.9%-3.3%$989.43M$599.25M12.97210SEPNSepterna2.0762 of 5 stars$21.96-1.9%$43.67+98.8%N/A$975.02MN/A0.00N/ANews CoveragePositive NewsZYMEZymeworks2.8479 of 5 stars$13.85+10.1%$18.83+36.0%+43.8%$953.99M$76.01M-9.25290BCAXBicara TherapeuticsN/A$17.50flat$43.00+145.7%N/A$952.28MN/A0.0032GYREGyre Therapeutics0.5939 of 5 stars$10.14+5.2%N/A-59.9%$948.30M$105.03M0.0040News CoverageGap UpPSTXPoseida Therapeutics3.7849 of 5 stars$9.52+0.1%$9.50-0.2%+182.4%$930.77M$64.70M-15.10260PAHCPhibro Animal Health4.1856 of 5 stars$22.74+0.3%$19.00-16.4%+93.0%$921.04M$1.05B52.561,940Positive News Related Companies and Tools Related Companies RCKT Competitors BCYC Competitors AVDL Competitors COLL Competitors SEPN Competitors ZYME Competitors BCAX Competitors GYRE Competitors PSTX Competitors PAHC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ITOS) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
